Previsión

El precio objetivo medio de los analistas es de +11,58€ (+61,28%). La mediana es de +11,58€ (+61,28%).

Comprar	8
Mantener	0
Vender	0

Noticias Ir al feed de noticias

CorMedix posts Q2 revenue $101.9m, raises full-year adjusted EBITDA guidance

CorMedix reported Q2 2026 consolidated revenue of $101.9 million and adjusted EBITDA of $58.7 million, driven by DefenCath sales and the acquired Melinta portfolio. The company reaffirmed full-year revenue guidance of $325–345 million and raised adjusted EBITDA guidance to $125–140 million, ending the quarter with $256.7 million in cash. CorMedix signed a multi-year DefenCath supply agreement with an additional large dialysis organization, bringing contracts with all five top U.S. providers, and plans pilot rollout in Q3. Management expects Mundipharma to submit an sNDA for REZZAYO prophylaxis in Q3 based on positive Phase III ReSPECT data, with potential FDA action in H1 2027, and is preparing commercial hires and modest incremental spend for a possible launch. » Más en finance.yahoo.com
CorMedix beats Q2 expectations and raises EBITDA forecast

CorMedix reported adjusted earnings of $0.29 per share for Q2 2026 on revenue of $101.9 million, beating analyst estimates. The company raised its adjusted EBITDA guidance for 2026 to $125–140 million, reported strong growth from DefenCath and the Melinta portfolio, and secured new supply contracts with all five leading US dialysis providers. The stock rose sharply premarket; management announced pilot programs and key regulatory milestones for REZZAYO but warned of reimbursement and customer-concentration risks. » Más en de.investing.com
CorMedix receives preliminary judicial approval for settlement in derivative lawsuit

The U.S. District Court for New Jersey granted preliminary approval for the proposed settlement in the consolidated shareholder derivative action against CorMedix (In re CorMedix Inc. Derivative Litigation; related case Raval v. Baluch). A final fairness hearing to approve the settlement is scheduled for September 23, 2026. CorMedix filed the necessary papers in an SEC filing; at the same time the company reported strong Q1 2026 revenue of $127.4 million with a slight EPS miss of $0.43. A federal appeals court also previously upheld the validity of patents for MINOCIN for Injection, marking a victory against Nexus Pharmaceuticals. » Más en de.investing.com

Datos financieros de la empresa

En el último trimestre, CORMEDIX INC. DL-,001 tuvo unos ingresos de 89,31M€ y un beneficio neto de 22,77M€

(EUR)	jun 2026	YoY
Ingresos	+89,31M	164,92%
Beneficio bruto	+67,58M	110,31%
Beneficio neto	+22,77M	35,36%
EBITDA	+50,28M	188,84%

Datos fundamentales

Métrica	Valor
Capitalización bursátil	+557,33M€
Número de acciones	78,45M
Máximo/mínimo de 52 semanas	+12,84€ - +5,26€
Dividendos	No
Beta	1,5
Ratio P/E	+3,44
Ratio PEG	+0,02
Ratio P/B	+1,41
Ratio P/S	+1,41

Perfil de la empresa

CorMedix Inc. ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung und Vermarktung von therapeutischen Produkten zur Vorbeugung und Behandlung von Infektions- und Entzündungskrankheiten in den Vereinigten Staaten und international konzentriert. Der führende Produktkandidat ist DefenCath/Neutrolin, ein neuartiges Antiinfektivum zur Verringerung und Vorbeugung von katheterbedingten Infektionen und Thrombosen bei Patienten, die zentrale Venenkatheter in klinischen Bereichen wie Hämodialyse, parenterale Ernährung und Onkologie benötigen. Das Unternehmen war früher als Picton Holding Company, Inc. bekannt und änderte im Januar 2007 seinen Namen in CorMedix, Inc. CorMedix Inc. wurde im Jahr 2006 gegründet und hat seinen Sitz in Berkeley Heights, New Jersey.

Nombre	CORMEDIX INC. DL-,001
CEO	Joseph Todisco
Sede	Parsippany, nj Estados Unidos
Sitio web	cormedix.com
Sector	Materiales
Industria	Productos químicos
Salida a bolsa	13/05/2010
Empleados	191